Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Health Technol Assess. 2020 Apr;24(18):1-94. doi: 10.3310/hta24180.
Observational data suggest that slowly advancing enteral feeds in preterm infants may reduce necrotising enterocolitis but increase late-onset sepsis. The Speed of Increasing milk Feeds Trial (SIFT) compared two rates of feed advancement.
To determine if faster (30 ml/kg/day) or slower (18 ml/kg/day) daily feed increments improve survival without moderate or severe disability and other morbidities in very preterm or very low-birthweight infants.
This was a multicentre, two-arm, parallel-group, randomised controlled trial. Randomisation was via a web-hosted minimisation algorithm. It was not possible to safely and completely blind caregivers and parents.
The setting was 55 UK neonatal units, from May 2013 to June 2015.
The participants were infants born at < 32 weeks' gestation or a weight of < 1500 g, who were receiving < 30 ml/kg/day of milk at trial enrolment.
When clinicians were ready to start advancing feed volumes, the infant was randomised to receive daily feed increments of either 30 ml/kg/day or 18 ml/kg/day. In total, 1400 infants were allocated to fast feeds and 1404 infants were allocated to slow feeds.
The primary outcome was survival without moderate or severe neurodevelopmental disability at 24 months of age, corrected for gestational age. The secondary outcomes were mortality; moderate or severe neurodevelopmental disability at 24 months corrected for gestational age; death before discharge home; microbiologically confirmed or clinically suspected late-onset sepsis; necrotising enterocolitis (Bell's stage 2 or 3); time taken to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days); growth from birth to discharge; duration of parenteral feeding; time in intensive care; duration of hospital stay; diagnosis of cerebral palsy by a doctor or other health professional; and individual components of the definition of moderate or severe neurodevelopmental disability.
The results showed that survival without moderate or severe neurodevelopmental disability at 24 months occurred in 802 out of 1224 (65.5%) infants allocated to faster increments and 848 out of 1246 (68.1%) infants allocated to slower increments (adjusted risk ratio 0.96, 95% confidence interval 0.92 to 1.01). There was no significant difference between groups in the risk of the individual components of the primary outcome or in the important hospital outcomes: late-onset sepsis (adjusted risk ratio 0.96, 95% confidence interval 0.86 to 1.07) or necrotising enterocolitis (adjusted risk ratio 0.88, 95% confidence interval 0.68 to 1.16). Cost-consequence analysis showed that the faster feed increment rate was less costly but also less effective than the slower rate in terms of achieving the primary outcome, so was therefore found to not be cost-effective. Four unexpected serious adverse events were reported, two in each group. None was assessed as being causally related to the intervention.
The study could not be blinded, so care may have been affected by knowledge of allocation. Although well powered for comparisons of all infants, subgroup comparisons were underpowered.
No clear advantage was identified for the important outcomes in very preterm or very low-birthweight infants when milk feeds were advanced in daily volume increments of 30 ml/kg/day or 18 ml/kg/day. In terms of future work, the interaction of different milk types with increments merits further examination, as may different increments in infants at the extremes of gestation or birthweight.
Current Controlled Trials ISRCTN76463425.
This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in ; Vol. 24, No. 18. See the NIHR Journals Library website for further project information.
观察性数据表明,在早产儿中缓慢增加肠内喂养可能会减少坏死性小肠结肠炎,但会增加晚发性败血症。速度递增奶量试验(SIFT)比较了两种喂养速度的增加。
确定每日增加 30ml/kg 或 18ml/kg 的喂养增量是否能改善极早产儿或极低出生体重儿的生存,且无中度或重度残疾和其他并发症。
这是一项多中心、两臂、平行组、随机对照试验。通过一个基于网络的最小化算法进行随机分组。由于安全和完全屏蔽医护人员和家长是不可能的,因此无法对其进行盲法。
该研究在英国 55 家新生儿单位进行,时间为 2013 年 5 月至 2015 年 6 月。
参与者为胎龄<32 周或体重<1500g 的婴儿,在试验入组时接受<30ml/kg/天的牛奶。
当临床医生准备开始增加喂养量时,将婴儿随机分配接受每日喂养增量 30ml/kg 或 18ml/kg。共有 1400 名婴儿被分配到快速喂养组,1404 名婴儿被分配到慢速喂养组。
主要结局为校正胎龄后 24 个月无中度或重度神经发育障碍的生存率。次要结局为死亡率;校正胎龄后 24 个月的中度或重度神经发育障碍;出院前死亡;微生物学证实或临床疑似晚发性败血症;坏死性小肠结肠炎(贝尔氏 2 或 3 期);达到全奶喂养所需的时间(连续 3 天耐受 150ml/kg/天);从出生到出院的生长;肠外喂养时间;重症监护时间;住院时间;由医生或其他健康专业人员诊断的脑瘫;以及中度或重度神经发育障碍定义的各个组成部分。
结果显示,1404 名快速增量组婴儿中有 802 名(65.5%)和 1404 名慢速增量组婴儿中有 848 名(68.1%)在 24 个月时无中度或重度神经发育障碍(校正风险比 0.96,95%置信区间 0.92 至 1.01)。两组在主要结局的个别组成部分或重要医院结局(晚发性败血症,校正风险比 0.96,95%置信区间 0.86 至 1.07)或坏死性小肠结肠炎(校正风险比 0.88,95%置信区间 0.68 至 1.16)的风险方面无显著差异。成本效益分析显示,快速喂养增量率在实现主要结局方面比慢速喂养增量率成本更低但效果也更差,因此被认为不具有成本效益。报告了四起意料之外的严重不良事件,每组各两起。没有一起被评估为与干预措施有因果关系。
该研究无法进行盲法,因此护理可能受到分配知识的影响。尽管对所有婴儿的比较都有很好的效果,但亚组比较的效果不佳。
在极早产儿或极低出生体重儿中,以每日 30ml/kg 或 18ml/kg 的速度增加牛奶喂养量时,并未发现对重要结局有明显优势。就未来的工作而言,不同牛奶类型与增量的相互作用值得进一步研究,在极早产或极低出生体重的婴儿中,不同的增量也可能值得进一步研究。
当前对照试验 ISRCTN76463425。
该项目由英国国家卫生研究所卫生技术评估计划资助,将在《卫生技术评估》杂志上全文发表;第 24 卷,第 18 期。欲了解该项目的更多信息,请访问 NIHR 期刊库网站。